Alitretinoin Anticancer Drugs Oncology Pharmacology Physiotherapy

Alitretinoin (Clinical Studies-6)

In this article we will discuss Alitretinoin (Clinical Studies-6)

In this article, we will discuss Alitretinoin (Clinical Studies-6). So, let’s get started.

At a median duration of monitoring of 16 weeks, only 15% of the 72 patients had relapsed. Alitretinoin gel would not be expected to affect development of new lesions in untreated areas and these were seen in about 50% of patients, at similar rates in treated and untreated patients, responders and non-responders. The patients’ assessment of their overall satisfaction with the drug effect on all treated lesions significantly favored Alitretinoin gel.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.